BioCentury on BioBusiness,
Pearl gets AstraZeneca into LAMA/LABA race, plus COPD triple therapy
Related tables, figures and sidebars
Triple advantage in COPD
Monday, July 15, 2013
plc's acquisition of Pearl Therapeutics Inc. gives the pharma an entry
point into the LAMA/LABA race and a platform to build out other combination
products. While the Pearl programs may be a couple of years behind competitors,
AZ is betting that better stability and dosing consistency could result in
products that are best in class.
On July 1, AstraZeneca
completed its acquisition of Pearl for $560 million up front. The biotech's
investors will be eligible for up to $450 million in development and regulatory
milestones, plus up to $140 million in sales milestones. Investors had put in
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2013 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
If you are a current subscriber, log in below or in the upper right corner of this
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial 4 Weeks of Access
Get a 4-week free trial subscription to see the important articles you are missing.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]